

1 Pathogen priming alters host transmission potential and predictors of transmissibility in a wild  
2 songbird species

3

4

5

6 Keywords: acquired protection, reinfection, transmission, *Mycoplasma gallisepticum*, virulence  
7 evolution

8

9 <sup>1</sup>Leon, A.E., <sup>2</sup>Fleming-Davies, A., <sup>3</sup>Adelman, J.S., and <sup>1</sup>Hawley, D.M.\*

10

11 <sup>1</sup>Department of Biological Sciences, Virginia Tech

12 <sup>2</sup>Department of Biology, University of San Diego

13 <sup>3</sup>Department of Biological Sciences, University of Memphis

14 \*Corresponding author: [hawleyd@vt.edu](mailto:hawleyd@vt.edu)

15

16

17

18

19

## 20 **Abstract**

21 Pathogen reinfections occur widely, but the extent to which reinfected hosts contribute to  
22 ongoing transmission is often unknown despite its implications for host-pathogen dynamics.  
23 House finches (*Haemorrhous mexicanus*) acquire partial protection from initial exposure to the  
24 bacterial pathogen *Mycoplasma gallisepticum* (MG), with hosts readily reinfected with  
25 homologous or heterologous strains on short timescales. However, the extent to which reinfected  
26 hosts contribute to MG transmission has not been tested. We used three pathogen priming  
27 treatments— none, intermediate (repeated low-dose priming), or high (single high-dose priming)—  
28 to test how prior pathogen priming alters the likelihood of transmission to a cagemate during  
29 index bird reinfection with a homologous or heterologous MG strain. Relative to unprimed  
30 control hosts, the highest priming level strongly reduced maximum pathogen loads and  
31 transmission success of index birds during reinfections. Reinfections with the heterologous  
32 strain, previously shown to be more virulent and transmissible than the homologous strain used,  
33 resulted in higher pathogen loads within high-primed index birds, and showed higher overall  
34 transmission success regardless of host priming treatment. This suggests that inherent differences  
35 in strain transmissibility are maintained in primed hosts, leading to the potential for ongoing  
36 transmission during reinfections. Finally, among individuals, transmission was most likely from  
37 hosts harboring higher within-host pathogen loads, while associations between disease severity  
38 and transmission probability were dependent on a given bird's priming treatment. Overall, our  
39 results indicate that reinfections can result in ongoing transmission, particularly where  
40 reinfections result from heterologous and highly transmissible strains, with key implications for  
41 virulence evolution.

42

43 **Importance**

44 As Covid-19 dramatically illustrated, humans and other animals can become infected with the  
45 same pathogen multiple times. Because individuals already have defenses against pathogen their  
46 immune systems have encountered before, reinfections are typically less severe, and are thought  
47 to be less contagious, but this is rarely directly tested. We used a songbird species and two  
48 strains of its common bacterial pathogen to study how contagious hosts are when their immune  
49 systems have some degree of prior experience with a pathogen. We found that reinfected hosts  
50 are not as contagious as initially infected ones. However, the more transmissible of the two  
51 strains, which also causes more harm to its hosts, was able to multiply more readily than the  
52 other strain within reinfected hosts, and was more contagious in both reinfected and first-infected  
53 hosts. This suggests that reinfections might favor more harmful pathogen strains that are better  
54 able to overcome immune defenses.

55

56

## 57 **Introduction**

58           Reinfections are a common but understudied feature of many host-pathogen systems (1–  
59 4), including those of humans (e.g., SARS-Cov-2; (5)). The apparent pervasiveness of  
60 reinfections is somewhat surprising given that vertebrate immune systems harbor specific  
61 immune memory (6), allowing hosts to respond more rapidly and effectively to reinfection with  
62 the same pathogen. Nonetheless, the immune memory generated by prior pathogen infection is  
63 often incomplete, meaning some degree of reinfection is possible in many systems (7–9). The  
64 extent to which acquired protection from infection is “incomplete” can also increase over time as  
65 an individual’s initial acquired immunity wanes, increasing the risk of reinfection (10, 11).  
66 Overall, the growing recognition that many vertebrate host-pathogen systems are characterized  
67 by reinfection potential, whether immediately following recovery from initial infection or after  
68 initial acquired protection has waned, has led to recent calls for epidemiological models that  
69 better account for variability in infection-derived immunity (reviewed in 9). Nonetheless, the  
70 extent to which reinfected hosts contribute to ongoing pathogen transmission is still not well  
71 understood, despite the importance of this question for both epidemiological and evolutionary  
72 dynamics of host-pathogen interactions (8, 12).

73           Because initial pathogen infection generates acquired immunity with some degree of  
74 specificity for many hosts, reinfections with the same pathogen generally result in lower  
75 pathogen loads, reduced disease severity, and/or increased survival relative to hosts infected for  
76 the first time, which have no acquired protection (e.g. 13). Lower pathogen loads during  
77 reinfection are predicted to reduce a reinfected host’s transmission potential relative to a host  
78 infected for the first time. In two studies that experimentally infected mice with *Plasmodium*  
79 *chabaudi* parasites and then rapidly treated them to create “immunized” mice, a three to four-

80 fold reduction in the density of transmission stage parasites was documented in previously  
81 immunized versus non-immunized mice (14, 15). Interestingly, the extent of reductions in  
82 transmission-stage parasites due to prior immunization was equivalent for homologous versus  
83 heterologous challenge strains of *P. chabaudi*, though heterologous strains were better able to  
84 transmit to mosquitoes (14). Further, numerous studies of vaccinated hosts across diverse taxa  
85 find that hosts challenged with the specific pathogen they were vaccinated against show lower  
86 transmission ability relative to unvaccinated hosts (16–19). Notably though, effects of  
87 vaccination on host transmission probability can also vary across pathogen strains. For example,  
88 vaccination of chickens for Marek’s virus reduced their transmission potential (relative to  
89 unvaccinated hosts) for a low-virulence strain of virus, but actually enhanced transmission  
90 potential of high-virulence strains (17). This occurred because vaccination against Marek’s virus  
91 generates incomplete immunity, protecting hosts from viral-induced mortality but not viral  
92 replication; together, this extends the infectious periods for virulent strains in vaccinated versus  
93 unvaccinated hosts, the latter of which rapidly succumb to virulent strains, often prior to  
94 transmitting (17). Thus, in addition to host pathogen loads, it is important to understand how  
95 immunization from prior infection or vaccination influences disease severity, which may  
96 determine reinfected host survival.

97         Other characteristics of pathogen strains, in addition to virulence, can potentially  
98 influence transmission potential during reinfection. Across taxa, inherent differences in strain  
99 within-host replication rates are often positively associated with transmission rates (20),  
100 suggesting that strain characteristics that influence within-host replication can, at least in some  
101 cases, predict transmission potential. High within-host replication rates are, in turn, associated  
102 with strain virulence in many systems (20, 21); for example, across ten parasite clones of *P.*

103 *chabaudii* infecting laboratory mice, parasite clone growth, virulence, and transmissibility were  
104 positively related (15). Although strains infecting immunized mice showed overall reductions in  
105 all three pathogen fitness traits, the positive relationships between clonal growth, virulence, and  
106 transmissibility persisted in immunized hosts, potentially favoring virulent strains able to  
107 generate sufficient within-host growth, and thus transmissibility, in immunized hosts (22, 23). In  
108 addition to traits such as virulence and transmissibility, antigenic relationships among strains can  
109 determine the ability to sufficiently overcome host immune protection generated by initial  
110 infection: for example, serum from humans previously infected with a variant of SARS-CoV-2  
111 showed stronger neutralization ability against homologous versus heterologous viral variants  
112 (24). Overall, such studies suggest that transmission success during reinfection can be strain  
113 specific, with transmission more likely during reinfections with heterologous and/or more  
114 virulent strains (14, 25, 26), provided such strains can better escape or overcome the acquired  
115 protection present in immunized hosts (22).

116         In addition to strain characteristics, the extent to which reinfected hosts transmit is likely  
117 dependent on the strength of acquired protection harbored by an individual at the time of  
118 reinfection. For example, the degree of SARS-Cov2 infectiousness (viral load) during  
119 reinfections or breakthrough infections was lowest for individuals who had both been vaccinated  
120 and experienced prior natural infection (27), and for malaria, individuals with prior infections in  
121 quick succession had serum stronger transmission-blocking immunity(28). Natural host-  
122 pathogen systems are inherently variable in the extent of initial pathogen exposure that hosts  
123 experience (e.g. 29, 30). Given that the strength of protection acquired from initial infection can  
124 vary with the dose (28, 29, 31) and frequency (28, 32) of prior pathogen exposure that a host

125 experiences, variation in the extent of pathogen priming is predicted to influence the likelihood  
126 of ongoing transmission during reinfection.

127         Natural systems in which reinfections are common, such as the bacterial pathogen  
128 *Mycoplasma gallisepticum* (hereafter “MG”) of house finches (*Haemorhous mexicanus*), allow  
129 examination of how the extent of pathogen priming alters host transmission potential during  
130 reinfection with distinct pathogen strains (e.g., homologous versus heterologous). MG causes  
131 seasonal epidemics of mycoplasmal conjunctivitis in house finch populations (33). MG is largely  
132 transmitted at bird feeders (34), and because this obligate pathogen is short-lived outside of the  
133 host (35), finches experience variable levels of exposure at contaminated feeders. Diseased  
134 finches in the wild recover at high rates (36), and experimental studies show that reinfections are  
135 characterized by significantly lower pathogen loads and disease severity relative to first  
136 infections (37). Nonetheless, recovered individuals remain susceptible to reinfection with both  
137 homologous and heterologous strains (8, 37, 38), with little evidence for additional protection  
138 associated with reinfection strain homology (8).

139         While prior work suggests that reinfections are common in this host-pathogen system, the  
140 likelihood and severity of reinfection varies with both the degree of initial pathogen priming and  
141 the identity of the reinfecting strain. Leon and Hawley (39) experimentally varied the degree of  
142 pathogen priming experienced by finches, finding that a single high-dose MG priming treatment  
143 results in stronger host protection from homologous reinfection than intermediate degrees of MG  
144 priming such as repeated, low-dose exposures. A follow-up study (40) using similar priming  
145 treatments three distinct MG strains found that reinfections of primed hosts by a heterologous,  
146 more virulent MG strain were associated with higher within-host pathogen loads relative to MG  
147 strains with lower virulence and within-host replication rates (8, 40). Because within-host

148 pathogen loads serve as a potential proxy for transmission likelihood, such results suggest that  
149 reinfection with a heterologous, more-virulent strain may result in higher transmission in this  
150 system, but work to date has not directly assessed transmission success. Given that prior studies  
151 have found discrepancies between effects of host immunization on proxies of transmission (such  
152 as the density of transmission-stage parasites) versus direct measures of transmission success  
153 (e.g. 14), it is key to examine effects of pathogen priming on between-host transmission success  
154 to fully uncover the importance of reinfections for pathogen ecology and evolution.

155         While no studies have examined MG transmission potential during host reinfection,  
156 several past studies quantified transmission in immunologically-naïve house finches. Among  
157 MG strains, higher within-host pathogen loads are associated with higher transmission rates (41),  
158 within a given strain, higher pathogen loads result in greater deposition of MG onto feeder port  
159 surfaces (42). In addition to pathogen loads, host disease severity is associated with transmission  
160 potential (43), with birds with more severely inflamed conjunctiva more likely to transmit to  
161 cagemates, even when accounting for the higher pathogen loads associated with higher disease  
162 severity (44–46). Given that reinfections in this system (8, 39) and others (15) are characterized  
163 by significant reductions in disease severity relative to hosts infected for the first time, the  
164 respective roles of pathogen load and disease severity in predicting transmission potential for  
165 pathogen-naïve and reinfected hosts is key for understanding the selective pressures on  
166 pathogens to cause higher disease severity (i.e. virulence) in hosts.

167         Here we test how pathogen priming alters transmission potential for hosts reinfected with  
168 one of two strains (homologous versus heterologous), and quantify individual correlates of  
169 transmission success (disease severity, pathogen load). Although we did not have sufficient  
170 strain replication to isolate effects of strain virulence *per se* on transmission success, our



171 reinfections used two strains that differ in virulence (8, 47), within-host replication rate (40, 47)  
172 and transmission potential (41). We specifically selected a more virulent strain as our  
173 heterologous strain for reinfections because MG strains collected from free-living house finches  
174 have increased in virulence over time (47, 48), with more virulent strains associated with higher  
175 transmissibility (41, 44). Thus, our experimental design mimicked a natural population in which  
176 individuals are most likely to be reinfected by either an endemic strain homologous to that which  
177 the host recently recovered from, or by an invading heterologous strain that has higher inherent  
178 transmissibility and virulence (44). To create variation in the degree of priming experienced by  
179 hosts, we varied the number and concentration of priming doses with a single MG strain (VA94)  
180 to create three priming levels: none, intermediate, or high. After recovery, we (re)-inoculated  
181 hosts and assessed effects of priming treatment on transmission success to a naïve cagemate  
182 during reinfection with one of two MG strains (the homologous strain, VA94, or the  
183 heterologous strain, NC06). Based on prior work (39, 40), we predicted the highest priming level  
184 would result in lowest host transmission potential. We also predicted that, consistent with prior  
185 work (40, 41), the heterologous, more virulent strain (NC06) would have higher overall  
186 transmission success, regardless of host priming treatment, with potential interactive effects of  
187 host priming and strain identity on transmission, as detected in the rodent-malaria system (e.g.  
188 14). Finally, based on prior work (44, 45), we predicted that disease severity would correlate  
189 with transmission potential in naïve hosts, but less so for reinfected hosts, which typically show  
190 stronger protection from disease versus pathogen loads (39).


191

## 192 **Methods**

### 193 *Experimental Design*

194            Seventy-eight captive, MG-naïve house finches (see *Supplement*) were randomly  
195 assigned to one of three priming treatments (n=26/group) that varied in both dose of pathogen  
196 exposure and total number of exposures (Figure 1). These priming levels - a negative control  
197 group (no priming), a low-dose repeat exposure group (“intermediate” priming), and a single  
198 high-dose exposure group (“high” priming) - were selected because they produced the greatest  
199 range in acquired protection in prior work, as measured by pathogen loads and disease severity  
200 during reinfection challenge (40). Inoculations for the intermediate priming group, which  
201 received six sequential exposures at 10<sup>1</sup> color changing units (CCU)/ml, were given every other  
202 day and designed so that all groups received their final inoculation on the same day to allow for  
203 the same window of recovery prior to challenge (Fig. 1).

204            Individuals were housed alone during priming treatment and given 39 days to recover  
205 from priming exposures, consistent with prior work (40). All birds then received a secondary,  
206 high-dose challenge with either a homologous or heterologous strain of MG (n=13 pairs/group;  
207 Fig. 1). At the time of secondary challenge, each of these 78 individuals was pair-housed with an  
208 MG-naïve cagemate to determine how pairwise transmission success varies with both the degree  
209 of pathogen priming and strain identity. Hereafter, individuals who acted as “transmitters” are  
210 referred to as “index” birds, and their immunologically-naïve cagemates used to assess  
211 transmission potential are referred to as “naïve” birds. Sex ratios of index birds were even for  
212 priming treatment groups (13:13 male:female). For secondary treatments, all transmission pairs  
213 were same sex, but because groups had a sample size of 13 (Fig 1), sex ratios were randomly  
214 assigned as either 6:7 male:female pairs or 7:6 female:male pairs. All protocols for animal use  
215 were approved by Virginia Tech’s Institutional Animal Care and Use Committee. See  
216 *Supplement* for capture and housing details.



217

218 *Figure 1.* Experimental design and timeline. Index individuals (housed alone for the priming  
 219 portion) were given one of three priming treatments (y-axis) with the *M. gallisepticum* strain  
 220 VA94 (blue squares), with treatments varying by number of priming exposures and dose (the  
 221 color gradient indicates variation in dose, with more intense color indicating increasing dose  
 222 concentration; CCU = color changing units). On day 39 post-priming treatment, all index birds  
 223 challenged with one of two strains: one homologous to that used in priming exposures (VA94,  
 224 seen in blue) or a heterologous strain (NC06, seen in yellow) and then pair-housed with an MG-  
 225 naive cagemate to assess pairwise transmission success.

226

### 227 *Pathogen inoculations*

228 Two strains were selected based on previous work demonstrating differences in the  
 229 maximum and average pathogen loads and virulence they produce in immunologically-naïve  
 230 house finches (8, 47). The house finch MG strain “VA94” (7994-1 7P 2/12/09) (49) was used for  
 231 all priming exposures, whether intermediate or high priming (Fig 1). Secondary challenge  
 232 inoculations were all at high dose and varied only in strain identity: either the priming strain  
 233 (homologous) or a heterologous strain “NC06” (2006.080-5 (4P) 7/26/12), used to represent a

234 hypothetical invading strain with higher transmissibility. Inoculations were administered via  
235 droplet installation directly into the conjunctiva (70uL total volume across both conjunctiva) via  
236 micropipette (see *Supplement*). The negative control (sham inoculation) group received 70uL of  
237 sterile media.

238

### 239 *Disease severity and pathogen load*

240 Disease severity was assessed by scoring the degree of visible inflammation, eversion,  
241 and exudate in conjunctival tissue (50) on a scale of 0-3 for each eye, and summing across eyes  
242 per individual within a given sampling date. Scoring was done blind to treatment. Pathogen load  
243 was assessed via swabbing of conjunctival tissue and MG-specific qPCR (see *Supplement*), with  
244 loads log<sub>10</sub> transformed for analysis.

245 Index birds were eye scored and sampled for pathogen load on post-secondary  
246 inoculation days (PSID) 4, 7, 14, 21 and 28. To obtain high resolution data on transmission  
247 timing, naïve cagemates were eye scored daily on PSID 5 through 18 and then on days 21, 23,  
248 25, 28, 32 and 35. Additionally, to ensure all individuals were still naive to MG just prior to the  
249 start of the experiment, we sampled for eye score and pathogen load on pre-inoculation day 19,  
250 as well as pre-challenge day 4 to obtain baseline data prior to re-inoculation. Responses to  
251 priming exposure levels have been previously examined (39), and are not included here.

252

### 253 *Transmission*

254           Pairwise transmission was quantified as successful when a previously naïve cagemate  
255 developed scorable eye lesions (>0). Although the use of eye score as the assay for transmission  
256 can miss low-level, subclinical infections, prior work comparing the two metrics (34) showed  
257 that using eye score as the transmission metric robustly captures naïve individuals with minimum  
258 pathogen loads (> 1349 copies across both conjunctiva) considered to be infectious in this  
259 system. Further, the use of eye score eliminates potential false positives, which are known to  
260 occur in our qPCR assay (39).

261

## 262 *Analyses*

263           All analyses were done using the statistical software R (51). In models where interactions  
264 were not significant, overall level effects were analyzed using Type II Likelihood Ratio tests  
265 using the car package in R (52). Whenever significant interactions were present, effects were  
266 analyzed using a Type III Likelihood Ratio (52). Post-hoc pairwise differences for significant  
267 interactions of interest were generated using the emmeans function and a Tukey adjustment for  
268 multiple comparisons.

269           *Within-Host Responses.* Because we were interested in the extent to which transmission  
270 success was a function of within-host responses, we analyzed both disease severity and pathogen  
271 load during secondary challenge of index birds with distinct priming treatments. As in our prior  
272 work (8), we ensured independence of repeated-measures data by analyzing only the maximum  
273 eye score and pathogen load for each index bird across four post-secondary challenge time-  
274 points (PSID 7, 14, 21, 28). For both models, fixed effects included priming treatment, secondary  
275 strain, and an interaction between the two effects (removed if not significant). To account for the

276 non-continuous nature of score data, maximum eye score was treated as an ordinal factor and  
277 analyzed using cumulative link models (CLM) in the ordinal package (53). Maximum pathogen  
278 load was analyzed using a generalized linear model with a Gamma distribution, chosen because  
279 pathogen load was positively skewed, and inverse link function (lme4 package in R, (54)).

280 Transmission. Pairwise transmission (Y or N), assessed via any visible eye lesions in  
281 cagemates, was analyzed using logistic regression with binomial distribution and a logit link  
282 function. Fixed effects included priming treatment and secondary challenge strain. An interaction  
283 between priming exposure and secondary strain was tested but not included in the final model, as  
284 we did not have sufficient statistical power to fit a model with interactions.

285 To determine which host factors (eye score, pathogen load, or both) are predictive of  
286 transmission success across priming treatments, pairwise transmission was also analyzed across  
287 individuals using a second logistic regression with binomial distribution and a logit link function.  
288 Because our analyses of eye score and pathogen load indicated that priming treatment influences  
289 each host response somewhat distinctly, we included priming treatment in interaction with  
290 maximum pathogen load and eye score in the model. Although previous work found correlations  
291 between pathogen load and eye score across MG strains (47), in this study, the two variables  
292 were correlated at a level of 0.48 (Pearson correlation coefficient) across individuals, allowing us  
293 to include these variables as independent fixed effects in our model (55).

294

295

## 296 **Results**


### 297 *Index Bird Within-Host Responses*

298 All birds recovered from priming-induced disease (eye scores = 0) by the time of  
299 reinfection challenge on day 39. The level of pathogen priming that an index bird received  
300 significantly predicted host disease severity (i.e., maximum eye scores) during reinfection  
301 challenge, with the lowest disease in birds that received high pathogen priming prior to challenge  
302 (CLM estimates: intermediate priming:  $-1.48 \pm 0.71$ ; high-dose priming:  $-3.34 \pm 0.93$ ); priming  
303 treatment LR Chisq= 31.8, df = 2,  $P < 0.0001$ ; Fig. 2A). As expected, the more virulent NC06  
304 strain produced higher maximum disease severity in birds than VA94 (strain[NC06]:  $1.59 \pm$   
305  $0.72$ ), but secondary strain was not significant in the overall model (secondary strain LR = 2.15,  
306 df = 1,  $P = 0.14$ ). There was no significant interaction between priming treatment and secondary  
307 strain identity on disease severity in index birds (priming:secondary LR = 5.10, df = 2,  $P =$   
308  $0.078$ ), suggesting effects of priming on disease severity were largely similar between the strains.


309 Pathogen loads just prior to reinfection challenge (day -4) were slightly elevated in index  
310 birds that received high priming treatment (Fig S1), suggesting complete clearance of high-dose  
311 priming had not universally occurred by the time of reinfection challenge. Nonetheless, birds that  
312 received high priming reached lower maximum pathogen loads during reinfection challenge than  
313 did birds with intermediate or no priming, indicating that residual pathogen from priming  
314 treatments was outweighed by effects of the protection acquired from priming (GLM assuming  
315 gamma distribution [parameters on *inverse* scale]: intermediate priming:  $0.049 \pm 0.036$ ; high  
316 priming:  $0.616 \pm 0.10$ ; priming treatment LR = 68.42, df = 2,  $P < 0.0001$ ; Fig. 2B). Priming  
317 treatment also interacted with strain identity to predict pathogen loads during reinfection  
318 (priming:secondary strain LR = 11.68, df = 2,  $P = 0.0023$ ). Specifically, in index birds given

319 high priming, hosts challenged with the heterologous, more virulent strain NC06 harbored  
320 significantly higher maximum pathogen loads than those challenged with VA94 (Table 1).  
321 Secondary strain did not have a significant main effect on pathogen loads (secondary strain LR =  
322 0.245,  $df = 2$ ,  $P = 0.62$ ).

323 A)



324 B)



Secondary Challenge Strain ■ VA94 - homologous ■ NC06 - heterologous

325

326

327 *Figure 2.* A) Maximum eye scores and B) pathogen loads after secondary challenge with one of  
328 two *Mycoplasma gallisepticum* strains (Left: homologous VA94, blue; Right: heterologous  
329 NC06, yellow) in index birds with distinct pathogen priming histories (x-axis: none,  
330 intermediate, or high). Each point represents maximum responses for each individual over four  
331 sample points. While eye scores are visualized as continuous here, they were analyzed as ordinal  
332 factors to account for their non-continuous distribution.



333 **Table 1.** Pairwise post-hoc comparisons for the significant interactive effect of priming (“prim.”)  
 334 treatment (none, intermediate=“int”, or high) and secondary strain (VA94 or NC06) on  
 335 maximum pathogen loads following secondary challenge. Interactive comparisons (strain  
 336 differences within priming treatment) are in italics for ease of visualization. Upper triangle (light  
 337 gray cells) gives Tukey-adjusted p-values ( $*p < 0.05$ ,  $**p < 0.01$ ), the bottom triangle (unfilled  
 338 cells) shows estimates for each pairwise comparison, and diagonal cells (dark gray, white text)  
 339 show predicted pathogen loads (emmeans) for each combination on the response scale. Within  
 340 the high priming treatment only, birds reinfected with NC06 had significantly higher pathogen  
 341 loads than birds infected with VA94.


<i>Priming: strain</i>	No priming VA94	Int. Prim. VA94	High Prim. VA94	No priming NC06	Int. prim. NC06	High prim. NC06
<b>No priming VA94</b>	5.37	0.735	<0.001**	0.996	1.000	0.0007**
<b>Intermediate VA94</b>	-0.049	4.24	<0.001**	0.436	0.656	0.0218*
<b>High priming VA94</b>	-0.616	-0.567	1.25	<0.001**	<0.0001**	0.0119*
<b>No priming NC06</b>	0.015	0.064	0.631	5.83	0.999	0.0002**
<b>Intermediate NC06</b>	0.004	0.054	0.620	-0.011	5.49	0.0005**
<b>High priming NC06</b>	-0.234	-0.185	0.382	-0.249	-0.239	2.38

343  
 344  
 345  
 346

#### *Transmission Success*

347 Pairwise transmission success was significantly lower, relative to unprimed birds, in  
 348 reinfected index birds that received intermediate or high priming prior to secondary challenge,  
 349 with the strongest reduction in transmission potential in the high priming group (logistic  
 350 regression with a binomial distribution: intermediate priming:  $-0.7703 \pm 0.381$ ; high priming: -  
 351  $1.581 \pm 0.470$ ; LR = 13.63, df = 2, P = 0.001; Fig 3). The heterologous, higher virulence NC06  
 352 strain had higher overall transmission success than the VA94 strain (NC06 strain:  $0.8627 \pm$   
 353  $0.351$ ; LR = 6.45, df = 1, P = 0.011; Fig. 3). Although NC06 was notably the only strain with  
 354 detectable transmission from high priming index birds, the low overall transmission success from  
 355 hosts with high priming (2/13 pairs for NC06, relative to 0/13 for VA94) made any statistical  
 356 interactions between secondary strain identity and priming treatment challenging to estimate.

357



358

359 *Figure 3.* Pairwise transmission of *Mycoplasma gallisepticum* from captive house finches with  
360 variable pathogen priming (x-axis) that were experimentally inoculated with one of two pathogen  
361 strains (Left: VA94 - homologous, seen in blue; Right: NC06 - heterologous, seen in yellow).  
362 Percent transmission (y-axis) from index birds (transmitters) was measured in pathogen-naive  
363 cagemates. Higher degrees of priming reduced an index bird's transmission potential to its  
364 cagemate for both strains, though the NC06 strain produced higher transmission regardless of  
365 host priming. Each treatment group had 13 pairs. Error bars represent binomial standard errors  
366 calculated using sample size.


367

### 368 *Host Factors Predictive of Transmission*

369

370 The model of index bird transmission (Y/N) with the strongest support included an index  
371 bird's maximum pathogen loads during secondary challenge, as well as the interaction between  
372 index bird maximum eye score and priming treatment. Specifically, across all priming  
373 treatments, index bird pathogen loads were positively associated with transmission probability

374 (logistic regression: pathogen load:  $3.93 \pm 1.52$ , LR = 14.58, df = 1,  $P < 0.001$ ). In contrast, the  
375 relationship between an index bird's maximum eye score and transmission success depended on  
376 a bird's priming treatment (eye score\*priming treatment: LR = 6.70, df = 2,  $P = 0.035$ ;  
377 interaction visualized in Fig. 4). For birds given intermediate priming, higher maximum eye  
378 scores during reinfection were associated with slightly lower transmission (intermediate  
379 priming\*score:  $-0.938 \pm 0.601$ ), while a positive effect of eye score was estimated for high  
380 primed birds (high priming\*score:  $46.1 \pm 5055.7$ ), although the model parameter could not be  
381 estimated with any precision due to the low number of high-primed birds with detectable eye  
382 score. The three-way interaction between pathogen load, disease severity, and priming treatment  
383 was not significant (LR = 0.44, df = 2,  $P = 0.80$ ) and was removed from the model.



384  
385 *Figure 4.* Successful pairwise transmission of *Mycoplasma gallisepticum* (filled symbols) from  
386 index house finches (n=78) given various priming treatments (symbols: unprimed birds = circles,  
387 intermediate priming = squares, high priming = triangles) was a function of the pathogen load of  
388 the index bird (y-axis), with successful transmission occurring only from index birds above a

389 threshold pathogen load of  $\log_{10} \sim 4.5$ . There were also significant effects of index bird  
390 maximum eye score (x-axis) in interaction with pathogen priming treatment, with higher eye  
391 scores associated with lower transmission success at intermediate priming levels (squares), while  
392 for high priming birds (triangle), intermediate eye scores, which were the highest maximum  
393 reached for this treatment, were positively associated with transmission likelihood.

394

## 395 **Discussion**

396 We show that pathogen priming significantly reduces transmission success during  
397 reinfections relative to birds that are infected for the first time. Nonetheless, reinfected hosts  
398 were still associated with a notable degree of successful pairwise transmission, particularly in  
399 cases where index birds had an intermediate priming level and reinfections were with a  
400 heterologous, higher virulence MG strain. Together, our findings suggest that reinfections  
401 meaningfully contribute to transmission dynamics in this system, particularly in cases that  
402 approximate our intermediate priming treatment, such as when pathogen priming in a population  
403 is variable, or acquired protection from previous infection has waned over time (37). As such,  
404 variation in the degree of acquired protection among hosts in natural populations, in systems  
405 where reinfections are common, can be an important impediment to transmission, placing  
406 selective pressure on invading pathogen strains to overcome host acquired protection.

407 Our main objective was to determine how the degree of pathogen priming, and thus the  
408 degree of acquired protection, alters host transmission potential during reinfection. For both  
409 strains examined, we found that the highest priming level resulted in strong reductions in  
410 transmission potential relative to unprimed hosts. These results are consistent with effects of host  
411 immunization on transmission likelihood in other key systems where this question has been  
412 examined, including mouse models (14, 15), and malaria (28) and SARS-Cov-2 in humans (27,

413 56–58). Together, these results demonstrate that prior pathogen infection or vaccination at levels  
414 sufficient to generate acquired protection can have strong effects on epidemic dynamics in wild  
415 populations, as documented in vaccinated human populations (e.g. 59), and likely provides  
416 strong selection on pathogens circulating in host populations where many individuals have  
417 acquired protection (17).

418 Our results also suggest that the degree of pathogen priming a host experienced has key  
419 effects on transmission success, potentially akin to the additive effects of vaccination and prior  
420 natural infection on the infectiousness of breakthrough SARS-Cov2 infections (27). Here, while  
421 our highest priming treatment caused strong reductions in transmission success for both strains,  
422 there were apparent, though not statistically significant, differences between the two strains in  
423 response to our intermediate priming level. The homologous VA94 strain showed no difference  
424 in transmission success between the no priming and intermediate priming levels. In contrast, the  
425 intermediate priming treatment resulted in fewer successful transmission events relative to  
426 unprimed birds for the heterologous NC06 strain. Future work should incorporate a low priming  
427 treatment such as a single, low-dose priming dose (39), to test whether there are strain-specific  
428 effects of lower degrees of pathogen priming on transmission in this system.

429 We also detected overall strain differences in transmission success akin to prior work  
430 (41), with the NC06 strain showing higher transmission success than VA94, regardless of a  
431 host's priming treatment. For within-host pathogen loads, however, effects of strain were  
432 dependent on host priming background, with the NC06 strain reaching significantly higher  
433 within-host pathogen loads than the VA94 strain within the high-priming group. This pathogen  
434 load advantage for NC06 may explain why there was successful transmission (~15%) of the  
435 NC06 strain even from hosts with the high priming level, whereas there were no instances of

436 successful transmission of the VA94 strain from hosts with the same high priming level. Overall,  
437 our findings align with mouse-malaria studies showing that parasite clone differences in growth  
438 rate and transmission are largely maintained in immunized hosts, despite overall reductions in  
439 average growth and transmission (15). Although heterology of the reinfection strain relative to  
440 the priming strain may partly explain the ability of NC06 to successfully replicate within and  
441 transmit during reinfection from hosts with the highest priming level, heterology is unlikely to be  
442 the main driver of these patterns: first, heterology is only a relevant mechanism in primed hosts,  
443 whereas transmission success of NC06 was substantially higher in unprimed hosts, for which the  
444 NC06 strain was the first MG strain that such hosts had been exposed to (and thus was not truly  
445 “heterologous”). Second, if heterology was an important driver of transmission potential during  
446 reinfection, we would predict that NC06 strain transmission would have been less affected by  
447 our intermediate priming level than was the homologous strain; instead NC06 appears more  
448 strongly affected (relative to unprimed birds) by intermediate priming than was VA94, the  
449 homologous strain. Finally, prior work in this system using larger numbers of MG strains found  
450 that strain virulence was a stronger predictor of reinfection likelihood than homology (8, 40),  
451 although effects of homology may result in small increases in acquired protection (8). Overall,  
452 our results complement prior work showing higher transmission rates (41, 44) for virulent MG  
453 strains in immunologically-naïve hosts, and suggest that this transmission advantage is  
454 maintained in the presence of strong acquired protection from priming.

455         We can use our results to hypothesize as to how detected effects of pathogen priming on  
456 transmission potential might ultimately influence virulence evolution in this system, although  
457 studies using replicate heterologous strains are needed to confirm effects of strain virulence on  
458 transmission potential during reinfection. For directly-transmitted pathogens, where virulence

459 typically reduces opportunities for transmission (60), high virulence should be favored when it is  
460 an unavoidable by-product of the high within-host replication needed for transmission given a  
461 contact (20). Thus, any within-host selective environment that requires higher levels of  
462 replication to achieve transmission should favor higher pathogen virulence, a prediction  
463 supported by prior studies in the mouse-malaria system (22, 23). Because pathogen priming led  
464 to significant reductions in pathogen loads and transmission success in reinfected hosts in our  
465 study, and maximum pathogen loads were associated with successful transmission, a host  
466 population with acquired protection from priming would favor a higher optimal pathogen  
467 virulence relative to an unprimed, naïve host population. Second, optimal virulence is predicted  
468 to increase whenever acquired protection in hosts reduces the costs of virulence to pathogens (8,  
469 15, 17) by preventing reinfected hosts from dying when infected with strains of higher virulence.  
470 These predictions were confirmed empirically in chickens vaccinated with Marek's virus (17),  
471 which are able to successfully transmit virulent strains in vaccinated flocks. Notably, priming at  
472 both intermediate and high levels in our study resulted in significantly lower index bird disease  
473 severity during reinfection, and disease severity is a relevant proxy for infection-mediated  
474 mortality in this system (61). Thus, while survival did not vary here (because birds survive MG  
475 infection in captive conditions where predators are absent), our results suggest that primed hosts  
476 in the wild are more likely to survive reinfections, potentially resulting in longer infectious  
477 periods for virulent strains in primed hosts (17). Overall, our findings, alongside prior modeling  
478 work on this system (8), suggest that acquired protection from priming in this system will favor  
479 higher optimal pathogen virulence.

480 Our results also reveal a key role for pathogen load in driving transmission success  
481 among individuals. In contrast to work by Bonneaud et al. (44) that did not detect effects of

482 strain-level variation in pathogen loads on MG transmission success, we found that individual  
483 variation in pathogen loads was positively associated with pairwise transmission success,  
484 regardless of host priming background. Although we also predicted that individual variation in  
485 disease severity would correlate with transmission as seen previously in this system (44, 45), we  
486 found that associations of disease severity with transmission success depended on a bird's  
487 priming treatment. For intermediate-primed birds, higher disease severity was associated with  
488 *reductions* rather than increases in transmission success, such that several birds with both high  
489 levels of disease severity and pathogen load did not successfully transmit to cagemates. While  
490 the reasons for this are unclear, one possibility is that because birds with high levels of disease  
491 severity also show behavioral morbidity during infection (61), high levels of disease severity  
492 may sometimes suppress rather than augment transmission opportunities in this system, and  
493 likely others (62). Indeed, prior work (45) found that MG-infected house finches that maintained  
494 foraging activity were more likely to transmit to cagemates, consistent with the idea that  
495 behavioral morbidity can suppress transmission. In contrast, for high-primed birds, disease  
496 severity appeared positively associated with transmission success, but due to the strong effects of  
497 high priming on protection from disease, we did not have sufficient numbers of high-primed  
498 birds with detectable eye scores to estimate this relationship with any precision. Overall, our  
499 findings suggest that effects of disease severity on transmission success differ between reinfected  
500 and naive hosts, with potential consequences for virulence evolution.

501 Overall, our results demonstrate that acquired protection from pathogen priming alters  
502 transmission success, potentially in distinct ways for different pathogen strains. Our results add  
503 to broader growing recognition (9, 12), that many epidemiological systems fall between the  
504 classically studied Susceptible-Infected-Recovered (SIR) systems, where recovered individuals



505 acquire complete protection that can wane over time, and Susceptible-Infected-Susceptible (SIS)  
506 systems, where hosts acquire no lasting protection from infection. As mathematical models  
507 continue to evolve to better capture this variation in infection- or vaccine-induced immunity (9,  
508 63, 64), it is important to empirically quantify how parameters such as transmission success vary  
509 with acquired protection in both vaccinated and reinfected populations to better understand  
510 transmission dynamics and predict the evolution of more harmful pathogens.

511

## 512 **Acknowledgments**

513 This work was funded by NIH grants R01GM105245 and R01GM144972 as part of the  
514 joint NIH-NSF-USDA Ecology and Evolution of Infectious Diseases program. Additional  
515 fellowship support for A. Leon was provided by the Virginia Tech IMSD program funded  
516 through NIH-NIGMS grant R25GM072767-09, the Virginia Tech College of Science Graduate  
517 Departmental Fellowship Award through the Department of Biological Sciences, the College of  
518 Science Roundtable Scholarship and the Southern Regional Education Board's Dissertation  
519 Writing Fellowship. We thank Courtney Thomason, Sahnzi Moyers, and Matt Aberle for their  
520 assistance with this project, as well as Kate Langwig, Joel McGlothlin, Rami Dalloul and Liwu  
521 Li for valuable feedback. We especially thank Natalie Bale and Eddie Schuler for their help with  
522 data collection, as well as Daphne Aguirre, Jennifer Holub and Camron Robertson.

523

524

## 525   **References Cited**

- 526   1.   Yamamoto T, Nagasawa I, Nojima M, Yoshida K, Kuwabara Y. 1999. Sexual transmission and  
527       reinfection of group B streptococci between spouses. *J Obstet Gynaecol Res* 25:215–219.
- 528   2.   Nardell E, McInnis B, Thomas B, Weidhaas S. 1986. Exogenous reinfection with tuberculosis in a  
529       shelter for the homeless. *N Engl J Med* 315:1570–1575.
- 530   3.   Islam N, Krajden M, Shoveller J, Gustafson P, Gilbert M, Buxton JA, Wong J, Tyndall MW, Janjua  
531       NZ, British Columbia Hepatitis Testers Cohort (BC-HTC) team. 2017. Incidence, risk factors, and  
532       prevention of hepatitis C reinfection: a population-based cohort study. *Lancet Gastroenterol Hepatol*  
533       2:200–210.
- 534   4.   Versteegh FGA, Schellekens JFP, Nagelkerke AF, Roord JJ. 2007. Laboratory-confirmed  
535       reinfections with *Bordetella pertussis*. *Acta Paediatr* 91:95–97.
- 536   5.   Pilz S, Theiler-Schwetz V, Trummer C, Krause R, Ioannidis JPA. 2022. SARS-CoV-2 reinfections:  
537       Overview of efficacy and duration of natural and hybrid immunity. *Environ Res* 209:112911.
- 538   6.   Netea MG, Schlitzer A, Placek K, Joosten LAB, Schultze JL. 2019. Innate and Adaptive Immune  
539       Memory: an Evolutionary Continuum in the Host’s Response to Pathogens. *Cell Host Microbe*  
540       25:13–26.
- 541   7.   Forshey BM, Reiner RC, Olkowski S, Morrison AC, Espinoza A, Long KC, Vilcarrromero S,  
542       Casanova W, Wearing HJ, Halsey ES, Kochel TJ, Scott TW, Stoddard ST. 2016. Incomplete  
543       Protection against Dengue Virus Type 2 Re-infection in Peru. *PLoS Negl Trop Dis* 10:e0004398.
- 544   8.   Fleming-Davies AE, Williams PD, Dhondt AA, Dobson AP, Hochachka WM, Leon AE, Ley DH,  
545       Osnas EE, Hawley DM. 2018. Incomplete host immunity favors the evolution of virulence in an  
546       emergent pathogen. *Science* 359:1030–1033.

- 547 9. Le A, King AA, Magpantay FMG, Mesbahi A, Rohani P. 2021. The impact of infection-derived  
548 immunity on disease dynamics. *J Math Biol* 83:61.
- 549 10. Breathnach AS, Riley PA, Cotter MP, Houston AC, Habibi MS, Planche TD. 2021. Prior COVID-19  
550 significantly reduces the risk of subsequent infection, but reinfections are seen after eight months. *J*  
551 *Infect* 82:e11–e12.
- 552 11. Goldberg Y, Mandel M, Bar-On YM, Bodenheimer O, Freedman LS, Ash N, Alroy-Preis S, Huppert  
553 A, Milo R. 2022. Protection and Waning of Natural and Hybrid Immunity to SARS-CoV-2. *N Engl J*  
554 *Med* 386:2201–2212.
- 555 12. Gomes MGM, White LJ, Medley GF. 2004. Infection, reinfection, and vaccination under suboptimal  
556 immune protection: epidemiological perspectives. *J Theor Biol* 228:539–549.
- 557 13. Raida MK, Buchmann K. 2009. Innate immune response in rainbow trout (*Oncorhynchus mykiss*)  
558 against primary and secondary infections with *Yersinia ruckeri* O1. *Dev Comp Immunol* 33:35–45.
- 559 14. Buckling A, Read AF. 2001. The effect of partial host immunity on the transmission of malaria  
560 parasites. *Proc Biol Sci* 268:2325–2330.
- 561 15. Mackinnon MJ, Read AF. 2003. The effects of host immunity on virulence–transmissibility  
562 relationships in the rodent malaria parasite *Plasmodium chabaudi*. *Parasitology* 126:103–112.
- 563 16. Singanayagam, Hakki, Dunning. Community transmission and viral load kinetics of the SARS-CoV-  
564 2 delta (B. 1.617. 2) variant in vaccinated and unvaccinated individuals in the UK: a .... *Lancet*  
565 *Infect Dis*.
- 566 17. Read AF, Baigent SJ, Powers C, Kgosana LB, Blackwell L, Smith LP, Kennedy DA, Walkden-  
567 Brown SW, Nair VK. 2015. Imperfect Vaccination Can Enhance the Transmission of Highly  
568 Virulent Pathogens. *PLoS Biol* 13:e1002198.

- 569 18. Chase-Topping ME, Pooley C, Moghadam HK, Hillestad B, Lillehammer M, Sveen L, Doeschl-  
570 Wilson A. 2021. Impact of vaccination and selective breeding on the transmission of Infectious  
571 salmon anemia virus. *Aquaculture* 535:736365.
- 572 19. Chase-Topping M, Xie J, Pooley C, Trus I, Bonckaert C, Rediger K, Bailey RI, Brown H, Bitsouni  
573 V, Barrio MB, Gueguen S, Nauwynck H, Doeschl-Wilson A. 2020. New insights about vaccine  
574 effectiveness: Impact of attenuated PRRS-strain vaccination on heterologous strain transmission.  
575 *Vaccine* 38:3050–3061.
- 576 20. Acevedo MA, Dillemath FP, Flick AJ, Faldyn MJ, Elderd BD. 2019. Virulence-driven trade-offs in  
577 disease transmission: A meta-analysis. *Evolution* 73:636–647.
- 578 21. Lipsitch M, Moxon ER. 1997. Virulence and transmissibility of pathogens: what is the relationship?  
579 *Trends Microbiol* 5:31–37.
- 580 22. Barclay VC, Sim D, Chan BHK, Nell LA, Rabaa MA, Bell AS, Anders RF, Read AF. 2012. The  
581 evolutionary consequences of blood-stage vaccination on the rodent malaria *Plasmodium chabaudi*.  
582 *PLoS Biol* 10:e1001368.
- 583 23. Mackinnon MJ, Read AF. 2004. Immunity promotes virulence evolution in a malaria model. *PLoS*  
584 *Biol* 2:E230.
- 585 24. Bekliz M, Adea K, Vetter P, Eberhardt CS, Hosszu-Fellous K, Vu D-L, Puhach O, Essaidi-Laziosi  
586 M, Waldvogel-Abramowski S, Stephan C, L’Huillier AG, Siegrist C-A, Didierlaurent AM, Kaiser L,  
587 Meyer B, Eckerle I. 2022. Neutralization capacity of antibodies elicited through homologous or  
588 heterologous infection or vaccination against SARS-CoV-2 VOCs. *Nat Commun* 13:3840.
- 589 25. Markov PV, Katzourakis A, Stilianakis NI. 2022. Antigenic evolution will lead to new SARS-CoV-2  
590 variants with unpredictable severity. *Nat Rev Microbiol* 20:251–252.

- 591 26. Mideo N, Kamiya T. 2022. Antigenic evolution can drive virulence evolution. *Nat Ecol Evol* 6:24–  
592 25.
- 593 27. Tan ST, Kwan AT, Rodríguez-Barraquer I, Singer BJ, Park HJ, Lewnard JA, Sears D, Lo NC. 2023.  
594 Infectiousness of SARS-CoV-2 breakthrough infections and reinfections during the Omicron wave.  
595 *Nat Med* 29:358–365.
- 596 28. Ranawaka MB, Munasinghe YD, de Silva DM, Carter R, Mendis KN. 1988. Boosting of  
597 transmission-blocking immunity during natural *Plasmodium vivax* infections in humans depends  
598 upon frequent reinfection. *Infect Immun* 56:1820–1824.
- 599 29. Konrad M, Vyleta ML, Theis FJ, Stock M, Tragust S, Klatt M, Drescher V, Marr C, Ugelvig LV,  
600 Cremer S. 2012. Social transfer of pathogenic fungus promotes active immunisation in ant colonies.  
601 *PLoS Biol* 10:e1001300.
- 602 30. Müller-Klein N, Risely A, Schmid DW, Manser M, Clutton-Brock T, Sommer S. 2022. Two decades  
603 of tuberculosis surveillance reveal disease spread, high levels of exposure and mortality and marked  
604 variation in disease progression in wild meerkats. *Transbound Emerg Dis* 69:3274–3284.
- 605 31. Weitzman CL, Ceja G, Leon AE, Hawley DM. 2022. Protection Generated by Prior Exposure to  
606 Pathogens Depends on both Priming and Challenge Dose. *Infection and Immunity*  
607 <https://doi.org/10.1128/iai.00537-21>.
- 608 32. Glover M, Colombo SAP, Thornton DJ, Grensis RK. 2019. Trickle infection and immunity to  
609 *Trichuris muris*. *PLoS Pathog* 15:e1007926.
- 610 33. Dhondt AA, Altizer S, Cooch EG, Davis AK, Dobson A, Driscoll MJL, Hartup BK, Hawley DM,  
611 Hochachka WM, Hosseini PR, Jennelle CS, Kollias GV, Ley DH, Swarthout ECH, Sydenstricker  
612 KV. 2005. Dynamics of a novel pathogen in an avian host: Mycoplasmal conjunctivitis in house  
613 finches. *Acta Trop* 94:77–93.

- 614 34. Adelman JS, Moyers SC, Farine DR, Hawley DM. 2015. Feeder use predicts both acquisition and  
615 transmission of a contagious pathogen in a North American songbird. *Proceedings of the Royal*  
616 *Society B: Biological Sciences* 282:20151429.
- 617 35. Dhondt AA, Dhondt KV, Hawley DM, Jennelle CS. 2007. Experimental evidence for transmission  
618 of *Mycoplasma gallisepticum* in house finches by fomites. *Avian Pathol* 36:205–208.
- 619 36. Faustino CR, Jennelle CS, Connolly V, Davis AK, Swarthout EC, Dhondt AA, Cooch EG. 2004.  
620 *Mycoplasma gallisepticum* infection dynamics in a house finch population: seasonal variation in  
621 survival, encounter and transmission rate. *J Anim Ecol* 73:651–669.
- 622 37. Sydenstricker KV, Dhondt AA, Ley DH, Kollias GV. 2005. Re-exposure of captive house finches  
623 that recovered from *Mycoplasma gallisepticum* infection. *J Wildl Dis* 41:326–333.
- 624 38. Dhondt AA, Dhondt KV, Hochachka WM, Ley DH, Hawley DM. 2017. Response of House Finches  
625 Recovered from *Mycoplasma gallisepticum* to Reinfection with a Heterologous Strain. *Avian Dis*  
626 61:437–441.
- 627 39. Leon AE, Hawley DM. 2017. Host Responses to Pathogen Priming in a Natural Songbird Host.  
628 *Ecohealth* 14:793–804.
- 629 40. Leon AE, Fleming-Davies AE, Hawley DM. 2019. Host exposure history modulates the within-host  
630 advantage of virulence in a songbird-bacterium system. *Sci Rep* 9:20348.
- 631 41. Williams PD, Dobson AP, Dhondt KV, Hawley DM, Dhondt AA. 2014. Evidence of trade-offs  
632 shaping virulence evolution in an emerging wildlife pathogen. *J Evol Biol* 27:1271–1278.
- 633 42. Adelman JS, Carter AW, Hopkins WA, Hawley DM. 2013. Deposition of pathogenic *Mycoplasma*  
634 *gallisepticum* onto bird feeders: host pathology is more important than temperature-driven increases  
635 in food intake. *Biol Lett* 9:20130594.

- 636 43. Hawley DM, Thomason CA, Aberle MA, Brown R, Adelman JS. 2023. High virulence is associated  
637 with pathogen spreadability in a songbird–bacterial system. *Royal Society Open Science* 10:220975.
- 638 44. Bonneaud C, Tardy L, Hill GE, McGraw KJ, Wilson AJ, Giraudeau M. 2020. Experimental evidence  
639 for stabilizing selection on virulence in a bacterial pathogen. *Evol Lett* 4:491–501.
- 640 45. Ruden RM, Adelman JS. 2021. Disease tolerance alters host competence in a wild songbird. *Biol*  
641 *Lett* 17:20210362.
- 642 46. Hawley, DM, Thomason C, Aberle M, Brown R, and Adelman JS. High virulence is associated with  
643 pathogen spreadability in a songbird-bacterial system.
- 644 47. Hawley DM, Osnas EE, Dobson AP, Hochachka WM, Ley DH, Dhondt AA. 2013. Parallel patterns  
645 of increased virulence in a recently emerged wildlife pathogen. *PLoS Biol* 11:e1001570.
- 646 48. Bonneaud C, Giraudeau M, Tardy L, Staley M, Hill GE, McGraw KJ. 2018. Rapid Antagonistic  
647 Coevolution in an Emerging Pathogen and Its Vertebrate Host. *Curr Biol* 28:2978–2983.e5.
- 648 49. Ley DH, Edward Berkhoff J, McLaren JM. 1996. *Mycoplasma gallisepticum* Isolated from House  
649 Finches (*Carpodacus mexicanus*) with Conjunctivitis. *Avian Diseases*  
650 <https://doi.org/10.2307/1592250>.
- 651 50. Sydenstricker KV, Dhondt AA, Hawley DM, Jennelle CS, Kollias HW, Kollias GV. 2006.  
652 Characterization of experimental *Mycoplasma gallisepticum* infection in captive house finch flocks.  
653 *Avian Dis* 50:39–44.
- 654 51. R Development Core Team. 2020. R: A Language and Environment for Statistical Computing  
655 (4.0.3).
- 656 52. Fox, Weisberg, Adler, Bates. Package “car.” : R Foundation for ....


- 657 53. Christensen RHB. 2015. ordinal—regression models for ordinal data. R package version 28:2015.
- 658 54. Bates D, Mächler M, Bolker B, Walker S. 2014. Fitting Linear Mixed-Effects Models using lme4.  
659 arXiv [statCO].
- 660 55. Dormann CF, Elith J, Bacher S, Buchmann C, Carl G, Carré G, Marquéz JRG, Gruber B, Lafourcade  
661 B, Leitão PJ, Münkemüller T, McClean C, Osborne PE, Reineking B, Schröder B, Skidmore AK,  
662 Zurell D, Lautenbach S. 2013. Collinearity: a review of methods to deal with it and a simulation  
663 study evaluating their performance. *Ecography* 36:27–46.
- 664 56. Abrokwa SK, Müller SA, Méndez-Brito A, Hanefeld J, El Bcheraoui C. 2021. Recurrent SARS-  
665 CoV-2 infections and their potential risk to public health - a systematic review. *PLoS One*  
666 16:e0261221.
- 667 57. Puhach O, Adea K, Hulo N, Sattoune P, Genecand C, Iten A, Jacquérior F, Kaiser L, Vetter P,  
668 Eckerle I, Meyer B. 2022. Infectious viral load in unvaccinated and vaccinated individuals infected  
669 with ancestral, Delta or Omicron SARS-CoV-2. *Nat Med* 28:1491–1500.
- 670 58. Bailey RI, Cheng HH, Chase-Topping M, Mays JK, Anacleto O, Dunn JR, Doeschl-Wilson A.  
671 Pathogen transmission from vaccinated hosts can cause dose-dependent reduction in virulence  
672 <https://doi.org/10.1101/830570>.
- 673 59. Anderson RM, May RM. 1985. Vaccination and herd immunity to infectious diseases. *Nature*  
674 318:323–329.
- 675 60. Anderson RM, May RM. 1982. Coevolution of hosts and parasites. *Parasitology* 85 (Pt 2):411–426.
- 676 61. Adelman JS, Mayer C, Hawley DM. 2017. Infection reduces anti-predator behaviors in house  
677 finches. *J Avian Biol* 48:519–528.
- 678 62. Kennedy DA. 2023. Death is overrated: the potential role of detection in driving virulence evolution.



- 679 Proc Biol Sci 290:20230117.
- 680 63. Katriel G. 2010. Epidemics with partial immunity to reinfection. *Math Biosci* 228:153–159.
- 681 64. Magpantay FMG, Riolo MA, DE Cellès MD, King AA, Rohani P. 2014. EPIDEMIOLOGICAL  
682 CONSEQUENCES OF IMPERFECT VACCINES FOR IMMUNIZING INFECTIONS. *SIAM J*  
683 *Appl Math* 74:1810–1830.
- 684 65. Hawley DM, Grodio J, Frasca S, Kirkpatrick L, Ley DH. 2011. Experimental infection of domestic  
685 canaries (*Serinus canaria domestica*) with *Mycoplasma gallisepticum*: a new model system for a  
686 wildlife disease. *Avian Pathol* 40:321–327.
- 687 66. Hartup BK, Mohammed HO, Kollias GV, Dhondt AA. 1998. Risk factors associated with  
688 mycoplasmal conjunctivitis in house finches. *J Wildl Dis* 34:281–288.
- 689 67. Grodio JL, Dhondt KV, O’Connell PH, Schat KA. 2008. Detection and quantification of  
690 *Mycoplasma gallisepticum* genome load in conjunctival samples of experimentally infected house  
691 finches (*Carpodacus mexicanus*) using real-time polymerase chain reaction. *Avian Pathol* 37:385–  
692 391.
- 693

694 Supplemental Materials

695



697 Figure S1. A) Disease severity (eye score) and B) pathogen loads over the course of secondary  
698 infection for index birds with distinct levels of pathogen priming given a secondary high-dose  
699 challenge with one of two strains of *Mycoplasma gallisepticum* (A: VA94; B: NC06). Exposure  
700 history (purple, circles – no priming; light blue, squares – intermediate priming; dark blue,  
701 triangular points – high priming) largely determined the extent of disease and pathogen load

702 across both strains, although the heterologous strain (NC06) produced higher levels of disease  
703 than the homologous strain (VA94), overall. Error bars represent standard error from the mean.

704

### 705 *Bird Capture and Housing*

706 Hatch-year house finches were captured in Montgomery County, VA in June-July 2016  
707 using a combination of mesh wire traps and mist-nets under permits from VDGIF (056090) and  
708 USFWS (MB158404-1). To ensure that birds used in our experiments had no previous exposure  
709 to MG in the wild, captive animals underwent a two-week quarantine protocol wherein they were  
710 monitored for visible signs of infection and blood sampled on day 14 post-capture to test for  
711 MG-specific antibodies (as per (65)). Only individuals that never showed clinical signs of  
712 infection, had not been housed with an infected individual, and were seronegative for pathogen-  
713 specific antibodies were included in the experiment (n=156 total).

714 All animals were pair-housed during quarantine, but index birds were single-housed prior  
715 to the start of and for the duration of the priming portion of the experiment. After recovery from  
716 priming exposures and immediately following secondary challenge, the index birds were then  
717 pair-housed with MG-naïve cagemates to assess pairwise transmission potential during  
718 reinfection. For the entirety of their time in captivity, finches were held at constant day length  
719 (12L:12D) and temperature, and were fed an *ad libitum* diet (Daily Maintenance Diet,  
720 Roudybush Inc., Woodland, CA). Individuals were given food in open-cup dishes for the  
721 priming portion of the study (when no transmission could occur due to individual housing).  
722 When inoculated birds were pair-housed with pathogen-naïve cagemates to quantify pairwise  
723 transmission, all pairs were given a two-port hanging tube feeder to mimic the feeder type most  
724 likely to facilitate transmission in the wild (34, 66).

725 *Inoculation*

726 Stock inocula were grown in Frey's broth media with 15% swine serum (FMS) and  
727 provided by D.H. Ley, North Carolina State University, College of Veterinary Medicine,  
728 Raleigh, NC, USA. All inocula were stored at -80°C and thawed and diluted immediately before  
729 use. Inoculation dilutions for priming exposures were calculated using the starting viable count  
730 of 10<sup>7</sup> CCU/ml of VA94. To control for the stress of extra handling and inoculation for birds in  
731 the repeated low-dose priming group, a randomly selected subset of individuals from the no  
732 priming and high-dose priming groups were given a sham inoculation of sterile FMS on priming  
733 days 1, 3, 5, 7 and 9 (Fig. 1). No effect of this sham treatment was detected on disease (F =  
734 0.048, df = 30, P = 0.83) or infection outcomes (F = 1.28, df = 12, P = 0.28) compared to control  
735 animals not given sham inoculations.

736

737 *Pathogen load quantification*

738 Both conjunctival sacs were swabbed for 5 seconds using separate sterile cotton swabs  
739 dipped in tryptose phosphate broth (TPB) and eluted in a single tube containing 300uL of TPB.  
740 Samples were kept on ice until frozen at -20°C and remained frozen until thawed for DNA  
741 extraction. DNA was extracted using Qiagen DNeasy 96 Blood and Tissue kits (Qiagen,  
742 Valencia, CA). Quantitative polymerase chain reaction (qPCR) was performed using a Bio-Rad  
743 C1000 CFX96 Real-time System (Hercules, CA). Primers and probes that target the Mgc2 gene  
744 of MG were used, and a standard curve of 2.98 x 10<sup>1</sup> to 2.98 x 10<sup>8</sup> copy numbers was produced  
745 using a plasmid containing a 303 bp Mgc2 insert (67). Cycling parameters used were as follows:  
746 95°C for 3 minutes then 40 cycles of 95°C for 3 seconds followed by 60°C for 30 seconds.